ReviewCancer2022
Evolving strategies for management of desmoid tumor.
Review in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 68 citations in OpenAlex.
- Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.The New England journal of medicine · 2023Trial
- Review
- Mesenteric desmoid tumor with diagnostic challenge mimicking a malignant small intestinal tumor: a case report.International journal of surgery case reports · 2026Article
- Systemic Therapies for Desmoid Tumors: A Review of Past, Present, and Future Treatments.Cancers · 2026Review
- Differential [European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Association between area deprivation index (ADI) and initial treatment among patients with desmoid tumorsSurgical oncology insight · 2026Article
- Genotype-guided conservative management of mesenteric desmoid tumors: A case report of intermediate-region APC mutations.Medicine · 2026Article
- Intravoxel incoherent motion combined with conventional MRI for the differentiation of benign, intermediate, and malignant fibrous soft-tissue tumors.Frontiers in oncology · 2026Article
- Evaluating the impact of surgical resection on desmoid tumour growth: a retrospective analysis from the National Cancer Centre Singapore.Frontiers in surgery · 2026Article
- Smooth muscle actin (SMA)-negative uninodular plexiform fibromyxoma: case report of a challenging atypical presentation of a rare gastric mesenchymal tumor in a 25-year-old female.AME case reports · 2026Article
- A Rapidly Growing Desmoid Tumor of the Anterior Chest Wall in a Young Woman: A Case Report.Cureus · 2025Article
- Exploring Clinical Studies and the FDA Adverse Event Reporting System (FAERS) Database for nirogacestat-related Adverse Events.Therapeutic innovation & regulatory science · 2025Article
- Dumbbell Spinal Desmoid Tumor Mimicking a Giant Schwannoma: Case Report and Literature Review.Journal of clinical medicine · 2025Article
- The impact of desmoid tumors: insights from the Desmoid Tumor Research Foundation Natural History Study, 2017-2023.Orphanet journal of rare diseases · 2025Review
- Surgical Resection and Abdominal Wall Reconstruction of a Rapidly Progressive Desmoid Tumor: A Case Report.Cureus · 2025Article
- A giant sporadic intra-abdominal desmoid tumor resection: a rare case report.International journal of surgery case reports · 2025Article
- Evaluating Management of Extra-Abdominal Desmoid Fibromatosis: A Retrospective Analysis of Treatments, Outcomes and Recurrence Patterns.Current oncology (Toronto, Ont.) · 2025Article
- Familial adenomatous polyposis family with clustering of psychiatric disorders.Japanese journal of clinical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Desmoid tumors (DTs) are rare soft tissue mesenchymal neoplasms that may be associated with impairments, disfigurement, morbidity, and (rarely) mortality. DT disease course can be unpredictable. Most DTs are sporadic, harboring somatic mutations in the gene that encodes for β-catenin, whereas DTs occurring in patients with familial adenomatous polyposis have germline mutations in the APC gene, which encodes for a protein regulator of β-catenin. Pathology review by an expert soft tissue pathologist is critical in making a diagnosis. Magnetic resonance imaging is preferred for most anatomic locations. Surgery, once the standard of care for initial treatment of DT, is associated with a significant risk of recurrence as well as avoidable morbidity because spontaneous regressions are known to occur without treatment. Consequently, active surveillance in conjunction with pain management is now recommended for most patients. Systemic medical treatment of DT has evolved beyond the use of hormone therapy, which is no longer routinely recommended. Current options for medical management include tyrosine kinase inhibitors as well as more conventional cytotoxic chemotherapy (e.g., anthracycline-based or methotrexate-based regimens). A newer class of agents, γ-secretase inhibitors, appears promising, including in patients who fail other therapies, but confirmation in Phase 3 trials is needed. In summary, DTs present challenges to physicians in diagnosis and prognosis, as well as in determining treatment initiation, type, duration, and sequence. Accordingly, evaluation by a multidisciplinary team with expertise in DT and patient-tailored management are essential. As management strategies continue to evolve, further studies will help clarify these issues and optimize outcomes for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.